Korean J Ophthalmol.  2019 Jun;33(3):298-300. 10.3341/kjo.2018.0091.

Intravitreal Dexamethasone Implant with Plasma Autoantibody Monitoring for Cancer-associated Retinopathy

• Kim MS
• Hong HK
• Park KH
• Woo SJ

• KMID: 2448872
• DOI: http://doi.org/10.3341/kjo.2018.0091

Abstract

No abstract available.

MeSH Terms

Dexamethasone*
Paraneoplastic Syndromes, Ocular*
Plasma*
Dexamethasone

Figure

• 

  Fig. 1 Summary of clinical and diagnostic features. (A) Color fundus photography showing no apparent abnormalities. (B) Fundus autofluorescence image shows abnormal hyper-autofluorescence in both eyes except the macula of the left eye (OS). (C) Initial spectral domain optical coherence tomography revealing photoreceptor disruption around the fovea more severe in the right eye (OD) than OS. Serial optical coherence tomography images revealed regeneration of the foveal photoreceptor layer after treatment OS and the re-established photoreceptor layer gradually deteriorated during 4 years of follow-up. (D) Initial visual field test revealing global constriction OS. On follow-up 24-2 and 10-2 Humphrey visual field tests OS 3 and 8 months after treatment, a central island of visual field appeared and persisted for 8 months. (E) Immunofluorescence imaging of the mouse retina treated with the patient plasma shows the autoantibody deposition (arrows) on the photoreceptors, photoreceptor cell nuclei, and ganglion cells (green, anti-human IgG Fc Ab; red, peanut agglutinin; blue, DAPI). (F,G) On Western blot analysis, retinal lysate treated with patient plasma was positive for the antibody reaction with a 30 kDa retinal protein (F, mouse retinal lysate; G, human retinal lysate). (H) Patient plasma was positive for the antibody reaction with 23 kDa of the recombinant recoverin protein. (I,J) During the course of treatment, decrease in the titer of anti-recoverin autoantibody was observed (I, 5 months; J, 12 months after treatment, respectively). PreTx = pretreatment.

Reference

1. Forooghian F, Macdonald IM, Heckenlively JR, et al. The need for standardization of antiretinal antibody detection and measurement. Am J Ophthalmol. 2008; 146:489–495.

2. Khan N, Huang JJ, Foster CS. Cancer associated retinopathy (CAR): an autoimmune-mediated paraneoplastic syndrome. Semin Ophthalmol. 2006; 21:135–141.

3. Grewal DS, Fishman GA, Jampol LM. Autoimmune retinopathy and antiretinal antibodies: a review. Retina. 2014; 34:827–845.

4. Kamei M, Fujitomi Y, Kondo Y, et al. Cancer-associated retinopathy after surgery for breast cancer: a case report and review of the literature. Surg Case Rep. 2018; 4:10.

5. Pohlmann D, Vom Brocke GA, Winterhalter S, et al. Dexamethasone inserts in noninfectious uveitis: a single-center experience. Ophthalmology. 2018; 125:1088–1099.